Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Category: CTEGD Blog

July 2025 Newsletter

Click on the image above to see the picture gallery with captions.

UGA biochemists create new tool to study biological process in parasites

Researchers in the West Laboratory are interested in how unicellular parasites thrive in their environments. Focusing on post-translational modifications of proteins, particularly a crucial process called glycosylation, researchers are gaining insights into how this basic life process in parasites can lead to better treatments for diseases. Read more.

CTEGD faculty member Jessica Kissinger earned the distinction of University Professor, a title bestowed on those who have made a significant impact on the university in addition to fulfilling their regular academic responsibilities. Read more

Diagnosing Chagas is complicated — in both people and canines. False negatives aren’t unheard of, leading people to not know they or their pets are infected. And that delays treatment. Read more.

Researchers at the University of Georgia’s Center for Tropical and Emerging Global Diseases have developed the first test to determine whether treatment for Chagas disease was effective. Read more.

Chester Joyner, assistant professor in the College of Veterinary Medicine’s infectious diseases department and member of CTEGD, is integrating molecular biology, immunology and vaccine development to develop new therapies needed to treat and prevent malaria. Read more.

Every year, malaria evades the immune defenses of nearly 250 million people. But Samarchith “Sam” Kurup is determined to outsmart the parasite before it strikes. Read more.

CTEGD's mission statement with photos depicting students, research, and poverty.

Support our mission with a financial gift TODAY! Support CTEGD.

Alumni News

Lilach Sheiner received the prestigious C.A. Wright Medal.

Hilary Danz took a new position at Sanofi. She is now the mRNA Center of Excellence New Vaccine Research Lead.

Mattie Pawlowic was awarded a Career Development Award from Wellcome Trust in March.

Justin Widener has left Boehringer Ingelheim and is now at Elano Animal Health.

Nuria Negrao was interviewed by the Northern California Chapter of the American Medical Writers Association.

Vivian Padin-Irizarry has been promoted to Associate Professor of Biology with tenure at Clayton State University.

Nathan Chasen has recently accepted an Assistant Professor position at the University of South Alabama.

Alona Botnar is now the Associate Director of International Market Access – Oncology Pipeline at AbbVie.

Hyun Woo (John) Kim started a new position at Helix Biostructures.

Congratulations, new graduates!

Katherine Moen (Moreno Lab)

Megna Tiwari (West Lab)

Trainee News

Clyde Schmidt (Kurup Lab) won the award for Outstanding Talk for his talk “Type-I IFNs induce GBPs and lysosomal defense in hepatocytes to control malaria” at the American Association of Immunologists annual meeting.

Alex Garrot (Kurup Lab) received a 3rd place poster award at the Woods Hole Immunoparasitology meeting.

CTEGD members in the news

Rick Tarleton:

Researchers secure funding to advance Chagas disease research (News-Medical.net)

Investigators are studying Chagas disease with a One Health approach (DVM360)

UGA and Texas A&M Researchers tackle Chagas disease in dogs and humans (WUGA)

Countable Labs Launches Single-Molecule DNA Counting System, PCR Application (GenomeWeb)

UGA Pioneers First Test for Chagas Disease Cure (Mirage)

UGA researchers develop first test of cure for Chagas disease (Newswise)

¿Se curó la infección de Chagas? Un nuevo test podría dar la respuesta (Infobae)

Chagas disease: Test for cure (Outbreak News Today)

AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease (Yahoo! Finance)

Brooke White: 

Researchers Warn Chagas Disease-Carrying Insects Have a “Secure Foothold in the U.S.” (Best Life)

Dennis Kyle:

Brain-eating amoebas are rare. But hot weather increases the risk (Washington Post)

Brain-eating amoeba: Who is most often infected? (Rochester First) (CBS42) (The Hill)

Podcasts featuring CTEGD members

Rick Tarleton discusses Chagas disease on Outbreak News Today.

Dan Colley shares about his career studying Schistosomes.

Chet Joyner discusses his research on the liver stage of malaria.

Doug Paton talks about his groundbreaking work on an incredible new way to treat malaria.

Recently published research

The Tarleton Research Group discusses the importance of persistence and dormancy in Trypanosoma cruzi infection and Chagas disease in a review published in Current Opinion in Microbiology.

Read more of the recently published research from all our labs.

Newly funded projects

Chet Joyner received an award from Abbott Laboratories for the production of Plasmodium isolates. He also received an award from the National Institutes of Health to establish P. vivax lines that grow in optimized culture conditions to develop a continuous, high yield culture system for P. vivax to support mechanistic studies that will lead to new therapies. A grant from Good Ventures Foundation will fund preclinical evaluation of safety, immunogenicity and protective efficacy against P. falciparum challenge of a nanoparticle vaccine encoding a Plasmodium MIF ortholog in Aotus nancymaae. Medcicnes for Malaria Venture has funded Joyner’s project for SERCAP testing for MMV2682.

Rick Tarleton received an award from the National Institutes of Health. The goal of this project is to complete adaptation of the rapid and inexpensive T. cruzi UltraPCR method for highsensitivity detection of T. cruzi, validate its use for confirming infection and monitoring treatment impact, and provide the justification for ultimately deploying this assay for human and veterinary diagnostic use. With his collaborators at Texas A&M University,  he also received a US Department of Homeland Security grant for a Canine Chagas Disease Prevalence, Prevention, and Operational Capability Protection Study.

Vasant Muralidharan, with collaborators at the University of California – Riverside, received a grant from the National Institutes of Health for Decoding the Role of Non-Coding RNAs in Gene Regulation.

Sam Kurup received a grant from the National Institutes of Health to study the mechanisms of human immune response to Plasmodium infection in the liver.

Chris West, in collaboration with colleagues at Virginia Polytechnic Institute, received two grants from the National Institutes of Health. One to study protist oxygen sensing in human disease and the other is to study the organization and function of the Toxoplasma daughter cell scaffold.

UGA researchers develop first test of cure for Chagas disease

New test protocol can detect low levels of Trypanosoma cruzi, the parasite that causes Chagas disease

Researchers at the University of Georgia’s Center for Tropical and Emerging Global Diseases have developed the first test to determine whether treatment for Chagas disease was effective.

An estimated 6 million to 8 million people worldwide are infected with Trypanosoma cruzi, the parasite that causes Chagas disease.

“Currently during drug trials, we can only determine if a drug fails,” said Rick Tarleton, Regents’ Professor in the UGA Franklin College of Arts and Sciences. “A test of cure can indicate if a drug succeeds in clearing the infection.”

Rick Tarleton of the Center for Tropical and Emerging Global Diseases

Part of the problem in determining if T. cruzi infection is cured by treatment is that the immune system is often very good at controlling the infection. Current tests are not sensitive enough to detect low levels of parasites.

“If you have a cup a tea with a little bit of tea leaf in it you may not get a tea leaf in every sip,” Tarleton said. “When there are so few parasites in the blood stream, it decreases the chances that a blood draw will contain any.

“We’ve taken two samples from the same individual at the same time—one sample tests positive, and the other tests negative. Which is right?”

Thousands die from Chagas each year

Chagas disease kills more than 10,000 people every year, mainly in Central and South America. But it is also a concern in the United States, where the Centers for Disease Control and Prevention estimates there are 280,000 people living with this disease.

And it’s not only humans that suffer from this disease. Many mammals, including wildlife and dogs, can also become infected.

The Tarleton group conducted large-scale PCR testing of samples from naturally infected macaque monkeys, dogs and humans. The team also fragmented the DNA to more evenly distribute it within the sample. Standard PCR testing doesn’t fragment DNA.

“If we go back to Rick’s tea leaf example, it’s like taking the whole tea leaf, breaking it up into tiny bits and then stirring the tea before taking a sip,” said Brooke White, lead researcher of the study. “This increases the chances of detecting DNA.”

New test accurately detects parasite infection in monkeys, dogs and humans

The naturally infected macaques were monitored over 12 months with monthly blood tests. A subset also had blood samples drawn seven times over four weeks. In addition to the exhaustive PCR testing, the researchers grew T. cruzi cultures from the blood samples, which confirmed that the new protocol accurately detects infection even when the parasite number is very low.

“Since the macaques acquired the infection in the same way as humans and dogs and their disease progression is the same, we are confident that this test will work in other species,” said Tarleton.

Collaborators at Texas A&M and in Argentina also provided naturally infected dog and human samples, respectively. The researchers saw similar results to the macaques.

A need for better drug treatment for Chagas disease

There is a need for new drug treatments for Chagas disease. But without a true test of cure, researchers only know what does not work. While the new protocol is effective, the researchers noted that it is also labor intensive and time consuming, which translates into being costly.

As part of the study, the researchers sought out technologies that could make the process faster and cheaper.

“This test of cure is a real game changer for drug treatment studies,” said White. “We are already working with other research groups in hopes of creating a quicker and cheaper method of testing parasite load in their drug treatment studies in macaques, dogs and humans.”

The researchers began collaborating with Countable Labs whose new technology allows for larger samples to be assayed faster. Reducing costs and increasing efficiency makes it much more likely for this test to be used in a clinical setting.

“Our goal now is to move this test out of the research lab and into a clinical diagnostic lab where it will be widely accessible for detecting human and dog infections and tracking treatment outcomes,” said Tarleton.

The study was co-authored by Daniel Hall of the UGA Department of Statistics. Additional co-authors include Carolyn Hodo, Sarah Hamer, Ashley Saunders and Susana Laucella.

This story was original published at UGA Today.

In the News: Rick Tarleton

UGA researchers develop first test of cure for Chagas disease (UGA Today)

UGA Pioneers First Test for Chagas Disease Cure (Mirage)

UGA researchers develop first test of cure for Chagas disease (Newswise)

¿Se curó la infección de Chagas? Un nuevo test podría dar la respuesta (Infobae)

Chagas disease: Test for cure (Outbreak News Today)

AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease (Yahoo! Finance)

Kurup wins prestigious PATH award for groundbreaking malaria research

Assistant Professor Samarchith “Sam” Kurup is the first UGA researcher to receive the Burroughs Wellcome Fund’s Investigators in Pathogenesis of Infectious Disease (PATH) award. Kurup studies the parasites that cause malaria and how they penetrate the body’s defenses, which could lead to more effective therapeutics. (Photo by Lauren Corcino)

Every year, malaria evades the immune defenses of nearly 250 million people. But Samarchith “Sam” Kurup is determined to outsmart the parasite before it strikes. Now, with the Burroughs Wellcome Fund’s prestigious Investigators in Pathogenesis of Infectious Disease (PATH) award in hand, his lab is one step closer.

Burroughs Wellcome recently announced its 2025 cohort of eight innovative scientists. Kurup is the first University of Georgia faculty member to receive this highly competitive award.

Growing up in India, Kurup saw malaria’s toll firsthand. That drove him to study parasites—first as a veterinarian, and then as a Ph.D. student. After completing training in veterinary medicine, he pursued his Ph.D. at UGA, studying another parasite that infects both humans and animals, Trypanosoma cruzi. He also began pairing his parasitology knowledge with immunology.

After graduating, Kurup returned as a postdoc to the study of Plasmodium, the parasite that causes malaria. In 2019, Kurup joined the faculty in the Franklin College of Arts and Sciences and the Center for Tropical and Emerging Global Diseases where he has established a robust research program.

“My lab is trying to understand how we, as hosts, fight malaria parasites in the liver,” said Kurup. “We know the liver cells have their own ‘home defense system’ and don’t have to call in other immune cells to handle the parasites. But somehow a few parasites are able to circumvent this defense system.”

In 2022, Kurup was awarded a five-year National of Institutes of Health grant to study how our liver cells target Plasmodium. Human malaria infection begins in what is called the liver stage of the parasite’s life cycle. After an infected mosquito bites a person, the parasite then travels to the liver where it replicates. While a person is not symptomatic at this point, the human immune system is already deploying its defenses. Kurup’s lab wants to understand why the human immune system is unable to fully clear the infection at this point.

“About 10% of the parasites are able to evade our immune responses within the hepatocytes,” said Kurup. “If we can figure out the parasite’s strategy, how they get through our defenses, then we have a chance of shutting them down completely.”

The Kurup lab has identified special proteins (which they call “exported effectors”) that the parasite releases. They believe these proteins help the parasite to slip past the human immune system. However, little is known about how they work.

“We want to find out what the parasite is targeting in the host cell,” said Kurup. “This would open up whole new doors in therapeutic research.”

This image shows a Plasmodium parasite (green) being surrounded and attacked by guanylate binding proteins (red), the host’s defense. The host cell nucleus is shown in blue. All of this action happens within the host’s liver cell, and Sam Kurup is trying to determine how the parasite is able to thwart such an attack. (Image courtesy of Kurup Lab)
This image shows a Plasmodium parasite (green) being surrounded and attacked by guanylate binding proteins (red), the host’s defense. The host cell nucleus is shown in blue. All of this action happens within the host’s liver cell, and Sam Kurup is trying to determine how the parasite is able to thwart such an attack. (Image courtesy of Kurup Lab)

Plasmodium falciparum is often resistant to current drug treatments. As the most widespread and lethal strain of malaria, it is critical to find new ways to treat the infection. Kurup believes that by targeting the malaria parasite in the liver, the disease can be stopped in its tracks.

The PATH award funds early career scientists to pursue cutting-edge research that may be considered too risky for traditional funding opportunities. The award to Kurup also comes with $505,000 in flexible research support over the next five years to identify the “exported effector” proteins, study their behavior, and explore how they interact with the host’s liver cells.

“In addition to being a recognition of the important work that we do as a team, this award is an endorsement to chasing bold ideas and having lofty goals,” Kurup said. “If we crack the parasite’s playbook, we could turn the tide against malaria.”

In the News: Rick Tarleton

Researchers secure funding to advance Chagas disease research (News-Medical.net)

Investigators are studying Chagas disease with a One Health approach (DVM360)

UGA and Texas A&M Researchers tackle Chagas disease in dogs and humans (WUGA)

Countable Labs Launches Single-Molecule DNA Counting System, PCR Application (GenomeWeb)

UGA biochemists create new tool to study biological process in parasites

Click on image below to view photo gallery with captions.

Researchers in the University of Georgia’s West Laboratory are interested in how unicellular parasites thrive in their environments. Focusing on post-translational modifications of proteins, particularly a crucial process called glycosylation, researchers are gaining insights into how this basic life process in parasites can lead to better treatments for diseases.

Christopher West
Chris West

Led by Distinguished Research Professor Christopher West, the team focuses on Toxoplasma gondii, a parasite that causes a chronic infection known as toxoplasmosis, and Dictyostelium discoideum, a soil-dwelling social amoeba commonly known as a cellular slime mold. Dictyostelium is an unrelated non-pathogenic model organism with a relatively simple life cycle, making it ideal for laboratory research.

Their colleagues at Boston University, Giulia Bandini and John Samuelson, discovered that dozens of nuclear and cytoplasmic proteins in Toxoplasma are unusually modified by a single sugar called fucose. There were potential parallels with a similar modification of host cell proteins with the key difference being the sugar involved-called GlcNAc, which is important for mediating host cell stress responses.

“This unprecedented finding raised new questions after we found that a similar process occurred in Dictyostelium,” said West, Distinguished Research Professor in Franklin College of Arts and Science’s Department of Biochemistry and Molecular Biology.

When the West lab identified the gene responsible for attaching O-fucose, the door was opened to study its function when it was knocked out in Toxoplasma and Dictyostelium.

“Though the cells still lived, both grew more slowly,” said West, a member of the Center for Tropical and Emerging Global Diseases. “The evidence indicated that several important proteins were less abundant, which consequently compromised their activity in cells.”

O-fucose is difficult to detect through traditional methods, which impedes learning more about its roles. To address this need, Megna Tiwari, a recently graduated biochemistry Ph.D. student in the West Lab, got together with Ron Orlando at the Complex Carbohydrate Research Center and GlycoScientific LLC to generate antibodies that only bind O-fucose on proteins. Her recent study published in mSphere illustrates the power of these antibodies to find and isolate O-fucose in the cell.

“Remarkably, dozens of new proteins were found to bear O-fucose and the images indicate that majority of them appear to be enriched at the nuclear periphery, inviting new ideas for O-fucose at this location,” West said.

This story was originally published at UGA Research https://research.uga.edu/news/uga-biochemists-create-new-tool-to-study-biological-process-in-parasites/

Scientists use ‘One Health’ model to fight Chagas disease

Supported by almost $4 million in new funding, researchers at the University of Georgia and Texas A&M are using improved detection and treatment methods to understand Chagas disease, a serious, often overlooked illness affecting both dogs and humans.

A team of researchers at the University of Georgia and Texas A&M University has received more than $4 million from federal and nongovernmental organizations to support research on Chagas disease.

The research will consist of multiple projects focused on the disease’s prevalence, diagnostics to detect the parasite that causes the disease, and treatment protocols to prevent infection and disease in dogs. The ultimate goal is to use the findings to help people as well.

Funded by a $3 million grant from the National Institutes of Health, UGA’s Rick Tarleton will co-lead a project focused on strategies to detect, treat and monitor treatment outcomes in dogs in Texas.  The goal is to establish the best practices that prevent the development of cardiac disease, one severe potential side effect of Chagas disease, and to establish resistance to possible future infection.

The researchers will work with dogs that were naturally infected with Chagas disease. Because the disease presents similarly in dogs as in humans, dogs are a good model for examining the effectiveness of the treatment.

Rick Tarleton of the Center for Tropical and Emerging Global Diseases
Rick Tarleton of the Center for Tropical and Emerging Global Diseases

“There are a number of important questions related to treatment efficacy and the protection that cured subjects have from future infection that cannot be easily addressed in humans but can be in these dog populations that are under intense transmission pressure in Texas,” said Tarleton, Regents Professor in UGA’s Franklin College of Arts and Sciences.

A growing threat to dog, human health

Tens of millions of people across the Americas have Chagas disease.

Chagas disease is a largely neglected disease. The parasite that causes it, Trypanosoma cruzi, is spread by blood-sucking insects known as kissing bugs, which can be found throughout North, Central and South America.

The disease, which commonly develops in humans and dogs, as well as many other mammals, often goes unnoticed in early stages. But a chronic infection can lead to serious heart and digestive system problems, making early diagnosis and prompt treatment important.

Although most human cases of Chagas disease are reported from South and Central America and Mexico, the parasite and its insect vector are found in abundance in the southern United States. Outdoor pets — particularly working dogs — face especially high risks of infection.

“These areas we are working in have 20% to 30% rates of new infections per year,” Tarleton said. “Those tend to be severe infections where the dogs either die or develop a disease that makes them unable to work.”

A kissing bug on a leaf in Houston, Texas.
Kissing bugs can carry the parasite that causes Chagas disease, and they’re particularly abundant in Texas and the southern U.S. (Getty Images)

Texas has become a hotspot of kissing bugs.

“Unfortunately, Texas has emerged as a hotspot of infected kissing bugs, infected wildlife and infected dogs across the landscape,” said Dr. Sarah Hamer, a professor in the Texas A&M College of Veterinary Medicine and a primary investigator on the projects.

“These projects will advance Chagas disease research to understand the process of natural infections, disease and effect of treatments,” Hamer said. “These projects combine many aspects of biomedical research. We’re conducting field and laboratory research, treating dogs, measuring clinical outcomes and studying ecological factors. It’s truly a ‘One Health’ approach.”

A One Health approach to Chagas disease research

Diagnosing Chagas is complicated — in both people and canines. False negatives aren’t unheard of, leading people to not know they or their pets are infected. And that delays treatment.

Even when the disease is diagnosed promptly, treating the condition can be challenging.

The go-to medications used to treat Chagas, as currently applied, are not reliably effective. But they’re currently the only treatment option. Tarleton’s previous work in mice and other species show that their effectiveness can be improved by altering the dosing regimen.

To address these issues, the researchers will track infected canines using a combination approach with sensitive tests to detect both the parasite DNA and the body’s response to infection. The team will simultaneously test a revised dosing strategy for the current antiparasitic treatment, providing fewer but high-level doses and extending the administration period to improve effectiveness.

Recording health information from such a large population of dogs will hopefully help us understand why the disease develops in different ways.” —Dr. Sarah Hamer, Texas A&M

“The drug we’re using is an existing treatment for Chagas disease in humans,” said Dr. Ashley Saunders, a professor in the Texas A&M College of Veterinary Medicine and a primary investigator on the projects. “But Dr. Tarleton has shown that the parasites aren’t susceptible to this drug when they’re dormant. By changing the drug delivery protocol to dosing over a longer period of time, when the dormant parasites become active again, they are killed by the drug.”

In a related study funded by the United States Department of Homeland Security, the researchers will also monitor DHS-owned working dogs that are often trained in areas where Chagas disease is prevalent. The goal is to understand how the dogs are exposed to the disease as well as the impacts it can have on the canines’ heart health, as well as to develop monitoring and treatment strategies for these working dogs.

“One of the reasons that monitoring dogs is so helpful is because Chagas disease can produce so many different subsets of health problems,” Saunders said. “Some dogs end up with a heart abnormality, but a large number continue living and working happily for many years. Others will die quite suddenly, before anyone knew they had the disease.”

“Recording health information from such a large population of dogs will hopefully help us understand why the disease develops in different ways,” Hamer said.

Advancing canine Chagas disease management

With continued support from the American Kennel Club Canine Health Foundation, the team will treat and monitor individual pet dogs brought to Texas A&M’s Small Animal Teaching Hospital while developing a staging system for Chagas disease in dogs.

“The staging system we develop will help us to categorize the severity of disease, making it easier to determine which dogs will benefit most from drug treatment,” Saunders said. “This scoring system will work hand-in-hand with our improved diagnostic and treatment plan.”

This story was originally published at UGA Today: https://news.uga.edu/scientists-use-one-health-model-to-fight-chagas-disease/

Chet Joyner receives Fred C. Davison Early Career Scholar Award

Studio portrait of Chester Chet Joyner.
Chester Joyner (Photo by Dorothy Kozlowski/UGA)

Chester Joyner, assistant professor in the College of Veterinary Medicine’s infectious diseases department and member of CTEGD, is integrating molecular biology, immunology and vaccine development to develop new therapies needed to treat and prevent malaria. His work addresses some of the biggest challenges in the field by studying Plasmodium vivax dormancy in the liver, investigating why malaria infections fail to generate long-lived immune responses and leading the preclinical testing of an innovative vaccine strategy that counteracts the parasite’s ability to inhibit development of long-lived immunity. Through these studies, his lab has overcome one of malaria’s greatest challenges: the inability to genetically manipulate P. vivax in the lab, developing novel techniques to introduce genetic modifications into P. vivax and opening new avenues for biology and vaccinology. Joyner has secured more than $7.3 million in research funding, authored 30 peer-reviewed publications and been invited to share his work at major international conferences. His work is shaping the future of malaria treatment and eradication strategies.

Originally published in Columns as part of their Honors Week coverage: https://news.uga.edu/2025-research-awards/